Journal of Parkinson s Disease · 2015 · 30 citations · 27 references
Life SciencesNeurosciencePharmacologyInflammationNeurodegenerationNeuropharmacologyBiomarkers Of NeurodegenerationInflammatory BiomarkersNeurodegenerative DiseasesNeurodegenerative DisordersNeuroinflammationParkinson DiseaseBiomarkersBiomarkers Of Parkinsonian DisordersOral Hypoglycemic TherapyOxidative Dna DamageParkinson Disease BiomarkersParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyPlacebo-controlled Efficacy Assessment
Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.
27
Julie St‐Pierre, Stavit Drori, Marc Uldry et al. · Cell · 2006 · 2.2K citations · Full text
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Joo‐Ho Shin, Han Seok Ko, Ho Chul Kang et al. · Cell · 2011 · 943 citations · Full text
Metabolomic profiling to develop blood biomarkers for Parkinson's disease
Mikhail Bogdanov, Wayne R. Matson, Lei Wang et al. · Brain · 2008 · 404 citations · Full text